# Phase 1 Heart Failure trials recruiting: 23 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 1 for Heart Failure that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Heart Failure trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/heart-failure

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 6, 2026 | NCT07861035 | A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic Cardiomyopathy | HieraBio Inc. | Phase 1 | Recruiting | Ischemic Cardiomyopathy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861035) |
| October 2, 2026 | NCT07856043 | \[11C\]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction | Stony Brook University | Phase 1 | Not yet recruiting | Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856043) |
| June 18, 2026 | NCT07656454 | A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy... | Novo Nordisk A/S | Phase 1 | Recruiting | Healthy Volunteers, Heart Failure | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656454) |
| May 22, 2026 | NCT07601087 | A Clinical Study of HRS-7156 in Healthy Participants | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Recruiting | Heart Failure | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601087) |
| April 24, 2026 | NCT07551167 | A Clinical Study of HRS-5765 in Healthy Participants | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Recruiting | Heart Failure | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551167) |
| April 23, 2026 | NCT07547540 | A Study of LY3971297 in Participants With Heart Failure | Eli Lilly and Company | Phase 1 | Recruiting | Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547540) |
| April 7, 2026 | NCT07516288 | Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1 | Recruiting | Dilated Cardiomyopathy (DCM), Heart Failure | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516288) |
| March 24, 2026 | NCT07490054 | Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure | Sponsor not shown (see the record) | Phase 1 | Recruiting | Chronic Heart Failure | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490054) |
| March 12, 2026 | NCT07465653 | A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction | Novartis Pharmaceuticals | Phase 1 | Recruiting | Heart Failure With Reduced Ejection Fraction | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465653) |
| March 2, 2026 | NCT07444398 | Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial | Sponsor not shown (see the record) | Phase 1 | Recruiting | Decompensated Heart Failure | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444398) |
| November 17, 2025 | NCT07230145 | A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure | Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Not yet recruiting | Heart Failure | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230145) |
| October 20, 2025 | NCT07218627 | A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure | Novo Nordisk A/S | Phase 1 | Recruiting | Heart Failure | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218627) |
| September 15, 2025 | NCT07172971 | Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy | Vanderbilt University Medical Center | Phase 1 | Recruiting | Duchenne Muscular Dystrophy (DMD) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07172971) |
| August 22, 2025 | NCT07137338 | A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy | Rocket Pharmaceuticals Inc. | Phase 1 | Recruiting | Dilated Cardiomyopathy (DCM) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07137338) |
| May 4, 2025 | NCT06956807 | Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells | Viscofan | Phase 1 | Not yet recruiting | CABG-patients, Heart Failure, Myocardial Infarction (MI) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956807) |
| February 18, 2025 | NCT06831825 | Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure | Medley Therapeutics | Phase 1 | Recruiting | Heart Failure With Reduced Ejection Fraction | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06831825) |
| January 13, 2025 | NCT06770023 | Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension | Mayo Clinic | Phase 1 | Recruiting | Lung Transplant, Pulmonary Hypertension | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06770023) |
| January 29, 2024 | NCT06228924 | Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC | Tenaya Therapeutics | Phase 1 | Recruiting | Arrhythmogenic Right Ventricular Cardiomyopathy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06228924) |
| January 17, 2024 | NCT06209359 | Mechanisms of Diuretic Resistance in Heart Failure, Aim 3 | Yale University | Phase 1 | Recruiting | Heart Failure, Diuretic Resistance | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06209359) |
| September 29, 2023 | NCT06061549 | Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction | Sardocor Corp. | Phase 1 | Recruiting | Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06061549) |
| March 3, 2023 | NCT05753059 | Mechanisms of Diuretic Resistance in Heart Failure, Aim 2 | Yale University | Phase 1 | Recruiting | Heart Failure | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05753059) |
| April 12, 2022 | NCT05323487 | Mechanisms of Diuretic Resistance in Heart Failure, Aim 1 | Yale University | Phase 1 | Recruiting | Heart Failure | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05323487) |
| November 17, 2016 | NCT02966665 | : Vascular Function in Health and Disease | Sponsor not shown (see the record) | Phase 1 | Recruiting | Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02966665) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Yale University | 3 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 2 |
| HieraBio Inc. | 1 |
| Stony Brook University | 1 |
| Sardocor Corp. | 1 |
| Vanderbilt University Medical Center | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| [Chengdu Suncadia Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chengdu-suncadia-medicine-co-ltd) | 1 |
| Rocket Pharmaceuticals Inc. | 1 |
| Mayo Clinic | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| Tenaya Therapeutics | 1 |
| [Beijing Suncadia Pharmaceuticals Co., Ltd](https://specstream.ai/data/clinical-trials/company/beijing-suncadia-pharmaceuticals-co-ltd) | 1 |
| Viscofan | 1 |
| [Shandong Suncadia Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shandong-suncadia-medicine-co-ltd) | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| Medley Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 4 |
| South Korea | 1 |
| United Kingdom | 1 |
| Canada | 1 |
| Poland | 1 |
| Pakistan | 1 |
| Germany | 1 |
| Japan | 1 |
| Moldova | 1 |
| Netherlands | 1 |
| Romania | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Structural engineering firms in the United States](https://specstream.ai/data/businesses/structural-engineering-firms/united-states)
- [Nigerian restaurants in the United States](https://specstream.ai/data/businesses/nigerian-restaurants/united-states)
- [Gastroenterology practices in the United States](https://specstream.ai/data/businesses/gastroenterology-practices/united-states)
- [Caribbean restaurants in the United States](https://specstream.ai/data/businesses/caribbean-restaurants/united-states)
- [Video production companies in the United States](https://specstream.ai/data/businesses/video-production-companies/united-states)
- [Polynesian restaurants in the United States](https://specstream.ai/data/businesses/polynesian-restaurants/united-states)
